论文部分内容阅读
目的探讨多西他赛联合奥沙利铂+卡培他滨(XELOX方案)治疗晚期胃癌的临床效果。方法选择2010年1月—2013年1月收治的晚期胃癌60例,按治疗方法分为对照组和观察组,每组30例。对照组给予单纯XELOX方案治疗,观察组在对照组基础上给予多西他赛治疗。均治疗4个周期。治疗结束后比较2组生活质量、近期临床疗效及生存时间,并记录治疗过程中毒性作用发生情况。结果 2组治疗后生活质量均较治疗前改善,且观察组改善程度优于对照组(P<0.05);观察组临床总有效率高于对照组,疾病无进展中位生存期和总中位生存期长于对照组(P<0.05);2组毒性作用发生率比较差异无统计学意义(P>0.05)。结论多西他赛联合XELOX方案治疗晚期胃癌可改善生活质量,提高近期临床疗效,延长生存时间,安全性较高。
Objective To investigate the clinical efficacy of docetaxel plus oxaliplatin plus capecitabine (XELOX regimen) in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer who were admitted from January 2010 to January 2013 were divided into control group and observation group according to the treatment method, 30 cases in each group. The control group was given simple XELOX regimen. The observation group was given docetaxel on the basis of the control group. All were treated for 4 cycles. After treatment, the quality of life, clinical efficacy and survival time of the two groups were compared, and the occurrence of toxic effects during the treatment was recorded. Results The quality of life of the two groups was improved after treatment, and the improvement in the observation group was better than that in the control group (P <0.05). The total effective rate in the observation group was higher than that in the control group. The disease progression-free median survival time and median The survival time was longer than that of the control group (P <0.05). There was no significant difference in the incidence of toxicity between the two groups (P> 0.05). Conclusion Docetaxel combined with XELOX regimen in the treatment of advanced gastric cancer can improve the quality of life, improve the short-term clinical efficacy, extend the survival time, and have higher safety.